Irinotecan Hcl-3-Water Koanaa (Irinotecan Hydrochloride)

Irinotecan Hydrochloride is used in oncology to target cancers that are treated with topoisomerase I inhibition.

• Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens.
• Advanced colorectal cancer: provides disease control as part of second‑line therapy.
• Other solid tumors: used in combination protocols for gastric, pancreatic, and lung cancers where topoisomerase I inhibition is indicated.

• Irinotecan Hydrochloride is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of DNA topoisomerase I. By stabilizing the topoisomerase‑DNA complex, SN‑38 prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of replication, and ultimately cancer cell death.

Irinotecan Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Nausea: may be managed with anti‑emetics.
• Fatigue: general tiredness experienced during treatment.
• Neutropenia: reduced white blood cell count increasing infection risk.

Serious or Rare Side Effects

• Severe neutropenic infection: life‑threatening bacterial infection.
• Febrile neutropenia: fever with low neutrophil count.
• Acute cholinergic syndrome: abdominal cramps, sweating, and bradycardia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks.

• Monitor blood counts: regular CBC to detect neutropenia.
• Assess liver function: dose adjustments may be needed for hepatic impairment.
• Evaluate renal function: consider renal status before administration.
• Use anti‑diarrheal prophylaxis: loperamide may reduce severity of diarrhea.
• Avoid in patients with known hypersensitivity to irinotecan or its excipients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Hydrochloride interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia and diarrhea.
• Concurrent use of other myelosuppressive agents: can exacerbate bone marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): increased bleeding risk due to mucosal damage.
• Anticholinergic drugs (e.g., atropine): may mask cholinergic syndrome symptoms.
• Proton pump inhibitors: possible alteration of drug metabolism, monitor efficacy.